[镓]Ga-NOTA-(TMVP1)用于卵巢癌患者血管内皮生长因子受体-3成像的首次评估。
First evaluation of [Ga]Ga-NOTA-(TMVP1) for imaging VEGFR-3 in ovarian cancer patients.
作者信息
Chen Xi, Li Fei, Si Yao, Han Liping, Lou Xiaoding, Xi Ling, Dai Jun
机构信息
Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430034, Hubei, China.
Key Laboratory of Cancer Invasion and Metastasis (Ministry of Education) Hubei Key Laboratory of Tumor Invasion and Metastasis, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430034, Hubei, China.
出版信息
Am J Nucl Med Mol Imaging. 2025 Apr 15;15(2):65-73. doi: 10.62347/FYYB3942. eCollection 2025.
To evaluate the safety and VEGFR-3 imaging effects of [Ga]Ga-NOTA-(TMVP1) in ovarian cancer patients. 13 patients with ovarian cancer were recruited and underwent radionuclide imaging with [Ga]Ga-NOTA-(TMVP1). The safety of [Ga]Ga-NOTA-(TMVP1) was assessed in vivo (including vital signs, biochemical indices, ECG, allergic reactions, etc.) and its imaging effect on VEGFR-3 was explored. A total of 1 patient with primary ovarian cancer and 12 patients with recurrent ovarian cancer, with an age range of 41-54 years, were included in the study. 13 ovarian cancer patients had a total of 49 F-FDG-positive lesions, 63.3% of which were positive for [Ga]Ga-NOTA-(TMVP1). The higher expression of VEGFR-3 in [Ga]Ga-NOTA-(TMVP1)-positive ovarian cancer lesions was found by immunohistochemical staining, which was positively correlated. Meanwhile, [Ga]Ga-NOTA-(TMVP1) is a safe radiotracer as no significant side effects have been found in the human. In conclusion, [Ga]Ga-NOTA-(TMVP1) enables precise molecular imaging of VEGFR-3 in ovarian cancer patients with a favourable safety profile, providing a new tool for the in vivo assessment of VEGFR-3 in ovarian cancer.
评估[镓]Ga-NOTA-(TMVP1)在卵巢癌患者中的安全性及VEGFR-3成像效果。招募了13例卵巢癌患者，采用[镓]Ga-NOTA-(TMVP1)进行放射性核素成像。在体内评估[镓]Ga-NOTA-(TMVP1)的安全性（包括生命体征、生化指标、心电图、过敏反应等），并探讨其对VEGFR-3的成像效果。研究共纳入1例原发性卵巢癌患者和12例复发性卵巢癌患者，年龄范围为41 - 54岁。13例卵巢癌患者共有49个F-FDG阳性病灶，其中63.3%的病灶[镓]Ga-NOTA-(TMVP1)呈阳性。通过免疫组化染色发现，[镓]Ga-NOTA-(TMVP1)阳性的卵巢癌病灶中VEGFR-3表达较高，呈正相关。同时，[镓]Ga-NOTA-(TMVP1)是一种安全的放射性示踪剂，在人体中未发现明显副作用。总之，[镓]Ga-NOTA-(TMVP1)能够对卵巢癌患者的VEGFR-3进行精确的分子成像，安全性良好，为卵巢癌中VEGFR-3的体内评估提供了一种新工具。
Zotero 插件